What Adriblastine Treats: Main Uses and Benefits

Adriblastine, which contains the active substance doxorubicin, is an antineoplastic antibiotic used to treat various types of cancer. It belongs to a group of medicines known as anthracyclines, which work by interfering with the genetic material of cancer cells, thereby slowing or stopping their growth and multiplication.

Primary Indications

This medication is utilized in the treatment of a wide range of solid tumors and hematological malignancies. The primary conditions for which it is prescribed include:

• Breast Cancer: It is frequently used both as a primary treatment for advanced stages and as part of adjuvant therapy to reduce the risk of recurrence after surgery.
• Lung Cancer: It is employed in the management of specific types of lung carcinoma, particularly small cell lung cancer.
• Ovarian Cancer: It is used to treat advanced ovarian tumors, often when other treatments have not been sufficiently effective.
• Bladder Cancer: It may be administered to treat tumors within the bladder.
• Hematological Malignancies: It is a core component in treating various cancers of the blood and lymphatic system, including:
  • Acute lymphoblastic leukemia
  • Acute myeloblastic leukemia
  • Hodgkin's lymphoma and non-Hodgkin's lymphoma
• Sarcomas: It is used in the treatment of bone sarcomas (such as osteosarcoma) and various soft tissue sarcomas.
• Pediatric Cancers: It is used in certain childhood cancers, including Wilms' tumor and neuroblastoma.

Therapeutic Benefits

The primary goal of treatment with Adriblastine is to induce remission or stabilize the progression of the disease. By targeting rapidly dividing cells, the medication offers several therapeutic benefits:

• Tumor Reduction: It can shrink the size of solid tumors, which may alleviate symptoms caused by the tumor mass or make surgical removal more feasible.
• Systemic Control: As a systemic therapy, it travels through the bloodstream to reach cancer cells that may have spread to other parts of the body.
• Combination Efficacy: It is often used in combination with other chemotherapy agents, as its mechanism of action can complement other drugs to increase the overall effectiveness of the treatment regimen.
• Palliative Support: In advanced cases where a cure may not be possible, it can be used to control the spread of the disease and improve the quality of life by managing cancer-related symptoms.

Regulatory References

1. NIH DailyMed official label information

The eligibility for Adriblastine (Doxorubicin hydrochloride) is strictly defined by regulatory authorities, primarily focusing on managing the risk of irreversible cardiotoxicity and ensuring adequate organ function.

Who Must Not Use Adriblastine (Contraindications)

Use is absolutely contraindicated for patients with:

• Severe Myocardial Insufficiency, recent Myocardial Infarction, or Severe Arrhythmias.
• Severe Hepatic Impairment (bilirubin > 5 mg/dL).
• Previous Anthracycline Treatment at Maximum Cumulative Lifetime Dose (e.g., ≥ 550 mg/m²).
• Persistent Myelosuppression, a Generalized Infection, or known Hypersensitivity to the drug.
• Pregnancy or currently Lactating.

Age-Group Status and Restrictions

Conditional Use is required for patients with Moderate Hepatic Impairment, mandating a dose reduction (e.g., 50% to 75%). Patients with prior Mediastinal Radiotherapy must also adhere to a lower lifetime cumulative dose limit. Contraception is required for both male and female patients of reproductive potential.

Interactions with other medicines and products for Adriblastine (Doxorubicin hydrochloride) are documented in regulatory labeling across several categories. The co-administration of live or live-attenuated vaccines is contraindicated due to the immunosuppressive effects of this antineoplastic agent.

A significant portion of the interaction profile involves pharmacokinetic interference. Medicinal products that inhibit the CYP3A4/CYP2D6 enzymes or the P-glycoprotein (P-gp) efflux transporter are advised against because they can increase the plasma concentrations of doxorubicin and its active metabolite. This category includes drugs like Ciclosporin. Conversely, inducers of these same metabolic pathways, such as the herbal product St. John's Wort, can decrease systemic exposure, potentially reducing the medicine's intended effects.

A severe pharmacodynamic interaction risk exists with other cardiotoxic agents (e.g., Trastuzumab, Cyclophosphamide), which may cause additive or potentiated damage to cardiac function. Additionally, a specific timing-based rule governs co-administration with Paclitaxel: Doxorubicin must be administered prior to Paclitaxel to manage a documented pharmacokinetic increase in drug exposure. The clinical relevance of these metabolic interactions is magnified in patients with pre-existing hepatic impairment, where reduced liver function inherently decreases doxorubicin clearance, intensifying the risk of accumulation.

Adriblastine (doxorubicin) functions by disrupting the fidelity of fundamental cellular processes, primarily targeting DNA and associated enzymes. Its mechanism involves two distinct actions. First, the molecule intercalates directly into the DNA double helix, inserting its planar rings between base pairs. This physical distortion creates a steric block that arrests the movement of DNA and RNA polymerases, thereby inhibiting DNA replication and gene transcription. Second, Adriblastine acts as an inhibitor of DNA topoisomerase II. The drug stabilizes the transient cleavage complex, trapping the enzyme after it has cut both DNA strands but preventing the subsequent religation. This persistence of double-strand DNA breaks is highly cytotoxic. Additionally, the drug's quinone structure facilitates a redox cycle, generating reactive oxygen species, such as superoxide and hydroxyl radicals. This oxidative stress contributes to macromolecular damage, collectively initiating the cascade leading to cellular self-destruction, known as apoptosis.

Official Administration and Dosage Guidelines

Adriblastine, which contains Doxorubicin, is primarily administered via intravenous (IV) injection or infusion for systemic treatment. An alternative, localized route is intravesical instillation for certain bladder conditions. Administration by the intramuscular or subcutaneous routes is strictly forbidden.

Dosing is based on the patient’s body surface area (mg/m^2) and typically follows a cyclic schedule. For single-agent systemic therapy, the standard dose generally ranges from 60 to 75 mg/m^2 per cycle, usually repeated every 21 to 28 days. When used in combination regimens, the dose is often reduced.

A critical instruction across all systemic uses is the maximum recommended cumulative lifetime dose, which is generally specified as 450 to 550 mg/m^2.

Preparation and Administration Requirements

The medicine, when supplied as a lyophilized powder, requires reconstitution with 0.9% Sodium Chloride Injection to a specified concentration. The IV dose must be administered slowly over a short duration, typically 3 to 10 minutes, into a secure, freely-flowing intravenous line. The solution must be protected from light until infusion is complete.

Dose reduction for patients with hepatic impairment is necessary based on serum bilirubin levels. For example, a 50% dose reduction is required for moderately elevated bilirubin. The repetition of cycles is dependent on the patient's recovery before the next dose is administered.

Research Evidence / Overview of Studies for Adriblastine

Adriblastine is a drug that has been evaluated across an extensive history of clinical research. The evidence base primarily consists of large-scale clinical trials and cooperative group studies that evaluated the drug as a component within multi-drug combination regimens. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. The following sections outline what researchers have studied across various conditions.

Evidence for Use in Hematological Malignancies

Research examined Adriblastine as a component within complex, multi-drug protocols for hematological conditions such as Hodgkin's Lymphoma and acute leukemias. Studies explored outcomes related to physical discomfort and systemic imbalance, focusing on measuring remission rates and survival outcomes.

Large cooperative group studies documented measurements of these outcomes across the patient groups observed. Since Adriblastine is almost always studied as one part of a multi-drug regimen, research does not precisely describe the extent of its independent contribution to the overall outcomes. The long-term effects of treatment often require follow-up beyond 10 years, and data for certain late consequences are still emerging.

Evidence for Use in Major Adult Carcinomas

Randomized Controlled Trials ( RCTs) and large Systematic Reviews were applied in research examining Adriblastine as part of regimens for major adult carcinomas, including breast and ovarian cancers. Studies explored outcomes reflecting daily functioning and overall disease progression, such as Invasive Disease-Free Survival ( IDFS) and objective tumor response measurements.

RCTs often involve specific, highly selected patient populations, which means the results apply only to the populations studied, and generalizability may be limited. Evidence quality varies across studies, and comparative evidence is sometimes uncertain in areas where older protocols serve as the reference standard.

What is Still Uncertain About Adriblastine Research

Certainty remains low regarding the isolated contribution of Adriblastine to overall outcomes, as its use is nearly always within a complex, multi-drug regimen. Long-term effects are not fully established for many contemporary combination protocols. Data for certain groups, such as elderly patients with specific comorbidities, remain insufficient, and follow-up durations were limited in several newer comparative studies.

Key Studies & References

1. Doxorubicin Hydrochloride Injection, USP Official Labeling (DailyMed)
2. Anthracyclines in the treatment of early breast cancer: an overview of the randomised trials

Common questions about Adriblastine (FAQ)

Q: Is it normal to feel very tired after an Adriblastine treatment session?

Yes, regulatory documents list fatigue (a feeling of weakness or being very tired) as a common adverse reaction for doxorubicin formulations. Official information indicates that this reaction can affect a significant percentage of patients receiving the medicine.

Q: What are the most common reasons a patient might stop using Adriblastine?

Official guidelines primarily instruct healthcare providers to modify or stop treatment in response to unacceptable toxicity. The most critical reasons for discontinuation are severe issues such as cardiotoxicity (heart damage) or severe myelosuppression (critically low blood counts).

Q: Does Adriblastine cause changes in appetite?

Yes, anorexia, which is defined as a loss or lack of appetite, is listed among the common adverse reactions in the official product information for doxorubicin. This indicates that a reduced desire to eat has been reported by patients using the drug.

Q: What kind of research is currently being done on new uses for Adriblastine?

Authoritative sources, such as the NIH, indicate that ongoing research themes for the active ingredient in Adriblastine focus on using it in combination with new targeted medicines. Studies also aim to develop new formulations designed to potentially lessen side effects and evaluate its role in the treatment of different types and stages of cancer.

Q: What is the connection between Adriblastine and blood cell counts?

Adriblastine is officially known to cause myelosuppression, a condition where the body's bone marrow activity is suppressed, leading to a decrease in blood cell counts. Regulatory documents indicate that the lowest point for these counts is commonly observed approximately 10 to 14 days following administration.

Q: How long does Adriblastine stay in your system after the last dose?

The medicine is eliminated from the body in several phases (multiphasic elimination). Official pharmacokinetic data states that the terminal half-life for doxorubicin generally ranges from 20 hours to 48 hours. This time frame describes how long the drug remains detectable as it is cleared from the system.

Q: What are the signs of a serious allergic reaction to Adriblastine?

Official information lists severe hypersensitivity reactions and anaphylaxis (a serious, whole-body allergic reaction) as possible adverse effects. These reactions involve the body's immune response and require medical attention.

Q: What kind of monitoring tests are usually done before or during Adriblastine therapy?

Regulatory documents mandate routine monitoring of blood cell counts (to check for myelosuppression), hepatic function (liver tests), and cardiac function. Cardiac monitoring often involves specific tests like the Left Ventricular Ejection Fraction (LVEF).

Q: Are there any known issues with combining Adriblastine with radiation therapy?

Yes, official labeling notes that doxorubicin can cause a reaction known as radiation recall phenomenon. This means that acute inflammatory reactions in the skin or mucosal tissues that were previously treated with radiation may recur or worsen after Adriblastine is administered.

Q: What is the difference between Adriblastine and its metabolite?

When the body processes the active ingredient in Adriblastine (doxorubicin), it forms a major compound called doxorubicinol, which is known as a metabolite. Official documents confirm that doxorubicinol is active and is part of the drug’s overall mechanism in the body.

Q: Does Adriblastine have a risk of causing a secondary cancer later on?

Yes, the official safety information lists secondary malignancies as a common adverse effect, meaning this reaction may affect 1% to < 10% of patients. Specifically, official documents mention an increased risk of developing Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).

Q: Are there any long-term effects of Adriblastine that are commonly reported?

Long-term effects described in authoritative literature primarily include delayed cardiotoxicity and the risk of secondary malignancies. Other possible long-term effects that have been noted include changes in reproductive function, such as amenorrhea (absence of menstruation) and potential for infertility.

Q: What happens if a scheduled Adriblastine dose is missed or delayed?

Official guidelines do not provide specific instructions for a simple missed dose but provide extensive protocols for delaying or withholding a dose due to specific toxicities. A dose may be postponed based on laboratory results, such as low blood counts, until the patient’s condition has recovered sufficiently for the next cycle.

Q: Are there different forms of Adriblastine (e.g., liposomal)?

Yes, the active ingredient in Adriblastine (doxorubicin) is also available in different FDA-approved formulations. One notable form is the liposomal formulation, where the drug is enclosed in a fat particle. This specific form has distinct indications and is not interchangeable with the conventional solution.

Q: How does Adriblastine affect the nervous system?

Authoritative literature mentions the potential for neurological issues associated with doxorubicin. These can include peripheral neuropathy (damage to the nerves outside the brain and spinal cord) and, less commonly, mild cognitive changes.

Q: Does Adriblastine interact with common vaccines, like the flu shot?

Official labels directly contraindicate live or live-attenuated vaccines because the drug is immunosuppressive. While inactivated vaccines (like the seasonal flu shot) are not strictly forbidden, the drug's effect on the immune system may reduce the effectiveness and the level of protection provided by the vaccine.

Q: What is the typical duration of an Adriblastine treatment course?

The length of the entire treatment course varies widely and is determined by the specific type of cancer being treated and the complete drug regimen being used. The medicine is given on a cyclic basis (e.g., every 21 or 28 days), and treatment is continued until disease progression or an unacceptable level of toxicity occurs.

Q: Why is Adriblastine sometimes described as a 'red' drug?

The drug is commonly referred to in patient circles as the 'red devil' due to its distinct bright red color when formulated. Official documents also note that the medicine imparts a red-orange coloration to the urine, a common, temporary effect that is not harmful.

Q: Is Adriblastine considered an essential medicine by global health organizations?

Yes, the active ingredient in Adriblastine (doxorubicin) is recognized as a critically important medicine globally. It is listed on the World Health Organization's (WHO) Model List of Essential Medicines, which confirms its status as one of the most vital medications needed in a basic health system.

Q: Can Adriblastine affect my ability to drive or operate machinery?

The product information states that because of the possible occurrence of undesirable effects such as dizziness or fatigue, patients should exercise caution when driving or operating machines.

Official Storage and Disposal Requirements

Adriblastine (Doxorubicin hydrochloride) must be stored and handled according to specific regulatory requirements for a cytotoxic agent.

Adriblastine is officially classified as a hazardous drug and requires special handling. Any unused medicine or associated waste materials must be disposed of in accordance with local procedures for cytotoxic agents, typically involving high-risk waste bags and high-temperature incineration. Unused portions from single-dose vials must be discarded.